Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes
mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would …

Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4)
inhibitors represent 2 distinct classes of incretin-based therapies used for the treatment of …

The discovery of incretin-based medications represents a major therapeutic advance in the
pharmacological management of type 2 diabetes mellitus (T2DM), as these agents avoid …

Background Several studies have shown that exenatide protects against ischemia-
reperfusion injury and improves cardiac function in patients with acute ST-segment elevation …

Incretin‐based therapies, the most recent therapeutic options for type 2 diabetes mellitus
(T2DM) management, can modify various elements of the disease, including hypersecretion …

The prevalence of type 2 diabetes is increasing, which is alarming because of its serious
complications. Anti‐diabetic treatment aims to control glucose homeostasis as tightly as …

The first clinical study to investigate effects of dipeptidyl peptidase‐4 (DPP‐4) inhibition was
published in 2002, and since then, numerous randomized controlled trials (RCTs) have …

摘要背景除了可以降解胰高血糖素肽‐1 (GLP‐1), 二肽基肽酶‐4 (DPP‐4) 还可以灭活几种趋化
因子, 包括间质细胞衍生因子‐1α (stromal cell‐derived factor‐1α, SDF‐1α) …

The influence of glucagon-like peptide-1 has been studied in several studies in patients with
acute myocardial infarction, but not in patients with non-ST-segment elevation myocardial …